AlbertoDM

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Prophylactic dex at absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity; dex attenuated facial nerve palsy, but not IEC-DNT, -PKS, -NP: https://t.co/pSngNexASn. #mmsm

[NEJM @NEJM]

In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: https://t.co/iiDNsw6CUW

Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML https://t.co/zsAPQjxEDb

[Dr. Chokri Ben Lamine @abouabdrahman0]

🦠 CMV AFTER CAR‑T: WHEN TO TREAT?

⚠️ No universally validated threshold—individualize.

🚨 Treat immediately:
🔴 Proven/probable CMV end-organ disease, regardless of plasma PCR.

🧪 Asymptomatic DNAemia:
🔸 High risk: consider treatment at ≥500 IU/mL
🔸 Lower risk: consider treatment at ≥1,000 IU/mL
🔸 <500 IU/mL: repeat PCR within 3–7 days; do not treat an isolated non-rising “blip”
📈 Treat earlier if rapidly rising.

🎯 High-risk features:
🔹 Prior CMV reactivation/allo-HCT
🔹 BCMA-directed CAR‑T
🔹 Corticosteroids >3 days
🔹 Prolonged immunosuppression for CRS/ICANS/IEC-HS
🔹 Heavy pretreatment or persistent cytopenia

🔍 Monitor high-risk patients weekly during weeks 2–6 after CAR‑T; extend if immunosuppression continues.

💊 Treatment:
✅ Ganciclovir/valganciclovir if counts permit
✅ Foscarnet if severe cytopenia—monitor renal function and electrolytes
⏳ Continue ≥14 days and until clinical and virological response.

🧠 MCQ: CMV PCR 180 IU/mL once, asymptomatic and stable—best action?
✅ Repeat PCR in 3–7 days.

🩺 OSCE pearl: Assess symptoms → PCR kinetics → immunosuppression → cytopenia/renal function → choose antiviral.

📚 Credit: ASTCT CMV Guidelines 2025
🔗 https://t.co/h4FtXJUl4i

#CARTcell #CMV #CellularTherapy #Hematology #TransplantInfections

[Ahmed Kotb @AhmedKo45911157]

🧬 Not all AML patients benefit equally from Ven+Aza.

A simple 4-gene signature can identify higher-, intermediate-, and lower-benefit groups—moving us one step closer to truly personalized AML therapy. 🎯

#EHA26 #AML #Venetoclax #PrecisionMedicine #Leukemia

[Ahmed Kotb @AhmedKo45911157]

Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy

https://t.co/ltdrOYkWNz

[Benlazar S M A @smbenlazar]

Current treatment algorithm: diffuse large B cell lymphoma https://t.co/h0IUjVtpSK #lymsm

[Benlazar S M A @smbenlazar]

How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas https://t.co/AL8QF4cocD #mdpicancers via @Cancers_MDPI #lymsm

[Ahmed Kotb @AhmedKo45911157]

👌Very nice review for Plasmablastic Lymphoma👏

[NEJM @NEJM]

This diagram shows the suggested diagnostic approach to disorders associated with eosinophilia. To learn more, read the latest Case Record of the Massachusetts General Hospital (@MassGeneralNews): https://nej.md/463iKqj

[Jordan Gauthier @drjgauthier]

💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update

If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0:

📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades.

🧪 Neutrophils:

Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded.

Stricter G4: threshold drops from <500 to <100/mm³.

🩸 Platelets (Thrombocytopenia):

Wider G3: Now covers 10k–50k (previously 25k–50k).

Stricter G4: threshold drops from <25k to <10k/mm³.

v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria.

Overall, IMO these new thresholds align better with clinical practice.

#ClinicalTrials #MedEd #OncTwitter #DrugSafety

[GELTAMO @geltamo]

Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas | Bone Marrow Transplantation https://t.co/QvRZScbCnp

[Hagop Kantarjian,MD @DrHKantarjian]

Review on #AML therapy
@MDAndersonNews #Leukemia
@BloodCancerJnl
https://t.co/QQDOfntNBS
#leusm

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

In honor of #MPNAwarenessDay
Here is all (OK most….) the #hemepath tricks you need to know to make a correct MPN diagnosis!!
Happy #hemepath ing…
��
*SL
👇🏼 are the major diagnostic categories… excluding CML… b/c that’s a totally different beast (or rabbit 🐰 #IYKYK)

[Anand Patel @Anand_88_Patel]

A very nice “how I treat” by Dr McMullin and @harrisoncn1 focused on treatment of low-risk polycythemia vera requiring cytoreduction #mpnsm

https://t.co/JvIduza2lk

[AmericanJournalofHematology @AjHematology]

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Including a practical diagnostic algorithm for #MPN
Free access: https://t.co/iKPOqoO32L
#hemepath #mpnsm

[AmericanJournalofHematology @AjHematology]

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management https://t.co/7vTxjIv9zl
#stemcelltransplant #HSCT #mpnsm

[Lucrecia Yañez @DrLucreciaYSS]

⁩Prevention 😷 and management 🖐️ of infectious complications 🦠 in patients 👨🏻‍🦳👵🏻👱🏻‍♂️👩🏼‍🦰 with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines ⁦@gellc⁩ https://t.co/7jSXr49hbf

[Ahmed Kotb @AhmedKo45911157]

🖊️How I Manage Acute Respiratory Failure in Patients with Hematological Malignancies
very nice cases
👆blood 2024
🌍https://t.co/D27LD3i5av
▶️#chest #pulmonary #radiology #hematology

[Vincent Rajkumar @VincentRK]

Our one stop website for myeloma risk:

-MM risk stratification
-SMM risk stratification
-MGUS risk stratification
-AL amyloid risk stratification

New:
-IFM Frailty score
-Waldenstrom prognosis
- iSTOP MM guide for marrow in MGUS

https://t.co/ARTG1zjKLm

https://t.co/f1qxlQDIyG

[Ahmed Kotb @AhmedKo45911157]

✔️Wonderful summarised algorithm for Lymphoma Classification
#lymphoma #classification #NHL